iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $4.72 million. The enterprise value is $2.16 million.
Important Dates
The last earnings date was Monday, November 17, 2025, after market close.
| Earnings Date | Nov 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 9.77 million shares outstanding. The number of shares has increased by 446.18% in one year.
| Current Share Class | 9.77M |
| Shares Outstanding | 9.77M |
| Shares Change (YoY) | +446.18% |
| Shares Change (QoQ) | +133.88% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 3.94% |
| Float | 9.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.43 |
| Forward PS | n/a |
| PB Ratio | 1.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.09.
| Current Ratio | 0.63 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -57.07 |
Financial Efficiency
Return on equity (ROE) is -296.20% and return on invested capital (ROIC) is -163.80%.
| Return on Equity (ROE) | -296.20% |
| Return on Assets (ROA) | -74.84% |
| Return on Invested Capital (ROIC) | -163.80% |
| Return on Capital Employed (ROCE) | -367.68% |
| Revenue Per Employee | $139,698 |
| Profits Per Employee | -$480,546 |
| Employee Count | 24 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.55% in the last 52 weeks. The beta is 1.80, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -87.55% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 39.35 |
| Average Volume (20 Days) | 439,193 |
Short Selling Information
The latest short interest is 67,653, so 0.69% of the outstanding shares have been sold short.
| Short Interest | 67,653 |
| Short Previous Month | 144,840 |
| Short % of Shares Out | 0.69% |
| Short % of Float | 0.70% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, iSpecimen had revenue of $3.35 million and -$11.53 million in losses. Loss per share was -$3.90.
| Revenue | 3.35M |
| Gross Profit | 722,540 |
| Operating Income | -12.13M |
| Pretax Income | -11.53M |
| Net Income | -11.53M |
| EBITDA | -11.87M |
| EBIT | -12.13M |
| Loss Per Share | -$3.90 |
Full Income StatementBalance Sheet
The company has $2.78 million in cash and $281,436 in debt, giving a net cash position of $2.50 million or $0.26 per share.
| Cash & Cash Equivalents | 2.78M |
| Total Debt | 281,436 |
| Net Cash | 2.50M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 3.07M |
| Book Value Per Share | 0.31 |
| Working Capital | -2.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.90 million and capital expenditures -$8,319, giving a free cash flow of -$6.90 million.
| Operating Cash Flow | -6.90M |
| Capital Expenditures | -8,319 |
| Free Cash Flow | -6.90M |
| FCF Per Share | -$0.71 |
Full Cash Flow StatementMargins
| Gross Margin | 21.55% |
| Operating Margin | -361.81% |
| Pretax Margin | -343.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -446.18% |
| Shareholder Yield | -446.18% |
| Earnings Yield | -247.61% |
| FCF Yield | -148.24% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 16, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iSpecimen has an Altman Z-Score of -16.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.06 |
| Piotroski F-Score | 1 |
